Do RCT-Proven Benefits of Minimally Invasive Surgery for Spontaneous Intracerebral Hemorrhage Translate into Real-World Settings? A GRADE-Assessed Systematic Review and Meta-Analysis
Background: Intracerebral hemorrhage is a highly lethal stroke subtype, yet uncertainty persists over the optimal surgical approach. Previous meta-analyses comparing minimally invasive surgery (MIS) with conventional craniotomy (CC) were confined to randomized trials, underpowered for several endpoints, and did not address real-world translatability or the full burden of complications.Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, the Cochrane Library, ClinicalTrials.gov, and grey literature from January 2000 to January 10, 2026. We included randomized and observational studies enrolling adults with spontaneous, non-traumatic intracerebral hemorrhage undergoing MIS versus CC. Two reviewers independently extracted summary data and assessed risk of bias. Outcomes were pooled using random-effects models, and meta-regression and sensitivity analyses were performed. GRADE certainty was rated separately for randomized, observational, and overall evidence pools, and trial sequential analysis was applied to functional outcomes and mortality.Findings: 76 studies involving 35,271 patients were included. In randomized trials, MIS improved favorable functional outcome (high certainty; RR 1·40, 95% CI 1·21–1·62; I²=35%), with trial sequential analysis confirming evidential sufficiency. This benefit was not clearly reproduced in observational data (RR 1·22, 0·95–1·57), indicating incomplete translation into routine practice. MIS also reduced mortality (moderate certainty; RR 0·73, 0·64–0·84), rebleeding (high certainty; RR 0·74, 0·60–0·92), systemic and surgery-related neurological complications, all with high certainty. ICU/hospital stay and blood loss also favoured MIS. Haematoma clearance was similar between groups.Interpretation: Extending prior trial-dominant literature, this synthesis demonstrates that MIS offers broader functional and safety advantages over CC, while revealing that trial efficacy does not automatically translate into routine care. Selective implementation, guided by patient severity, technique choice, and system-level standardization, is essential. Endoscopic and port-based MIS for patients with intermediate severity were most beneficial. Functional benefit warrants guideline reappraisal. Definitive mortality evidence requires adequately powered trials with prospectively designated mortality endpoints.